Blueprint Medicines

79 articles with Blueprint Medicines

• Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership

  1/11/2021

  -- AYVAKIT™ (avapritinib) granted FDA breakthrough therapy designation for the treatment of moderate to severe indolent systemic mastocytosis -- -- Positive top-line results from Phase 1 healthy volunteer trial of BLU-263 support plans to initiate Phase 2 HARBOR trial in non-advanced systemic mastocytosis in mid-2021 -- -- Nominated potential first-in-class development candidate targeting double-mutant EGFR, deepening leadership in lung cancer --

• Blueprint Medicines Announces R&D Leadership Transitions

  1/11/2021

  -- Becker Hewes, M.D., promoted to Chief Medical Officer -- -- Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development -- -- Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2021

  1/5/2021

  Blueprint Medicines Corporation announced that, effective on January 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,675 shares of its common stock and an aggregate of 3,837 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  Blueprint Medicines Corporation announced that, effective on December 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 16,354 shares of its common stock and an aggregate of 8,174 restricted stock units to eight new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

  12/1/2020

  -- Once-daily treatment with GAVRETO demonstrated robust efficacy in patients with RET-altered thyroid cancers, including prolonged duration of response -- -- Expands GAVRETO label following initial approval for RET fusion-positive non-small cell lung cancer in September 2020 -- -- Blueprint Medicines and Genentech are co-commercializing GAVRETO in the U.S. --

• Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition

  11/23/2020

  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to report data presentations highlighting the medical needs in systemic mastocytosis (SM) and the broad potential of AYVAKIT™ (avapritinib) across multi

• 

  FDA Action Alert: Blueprint, Liquidia, Revance, Rhythm and Merck

  11/23/2020

  The U.S. Food and Drug Administration (FDA) has a busy end of November planned, with numerous PDUFA dates to address. Here’s a look at the upcoming week.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 03, 2020

  11/3/2020

  Blueprint Medicines Corporation announced that, effective on November 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 16,513 shares of its common stock and an aggregate of 8,255 restricted stock units to five new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

  10/22/2020

  Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Blueprint Medicines Corporation announced that, effective on October 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 77,118 shares of its common stock and an aggregate of 38,557 restricted stock units to five new employees

• Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

  9/25/2020

  -- First highly effective treatment option approved in Europe for PDGFRA D842V mutant GIST -- -- 95% ORR and 22.1 month median DOR in patients with unresectable or metastatic PDGFRA D842V mutant GIST in the NAVIGATOR trial1 --

• Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis

  9/22/2020

  -- 76% confirmed ORR in EXPLORER, with a median duration of response of 38.3 months -- -- 75% confirmed ORR in PATHFINDER, with a median duration of response not reached -- -- AYVAKIT safety profile reinforced at 200 mg QD dose in advanced SM -- -- Plan to submit supplemental new drug application to FDA for advanced SM in fourth quarter of 2020 -- -- Blueprint Medicines to host investor conference call today at 8:30 a.m. ET -- &

• Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer

  9/20/2020

  60% ORR in patients previously treated with vandetanib or cabozantinib, and 74% ORR in treatment-naïve patients

• Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020

  9/17/2020

  -- BLU-945 demonstrates potent EGFR pathway inhibition against on-target resistance mutations -- -- BLU-945 shows exquisite wild-type EGFR and kinome selectivity, enabling potential for combination strategies -- -- Plan to initiate international Phase 1 dose-escalation trial of BLU-945 in patients with treatment-resistant EGFR-mutated NSCLC in 1H 2021 --   [17-September-2020]  

• Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference

  9/9/2020

  Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will participate virtually in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference

• Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  9/5/2020

  -- GAVRETO, the only once-daily RET-targeted therapy, demonstrated durable efficacy, with complete responses in a subset of patients -- -- Blueprint Medicines and Genentech will co-commercialize GAVRETO in the U.S. -- -- FDA approval underscores Blueprint Medicines' commitment to deliver a portfolio of transformative precision therapies to patients with NSCLC -- -- NDA accepted by FDA for pralsetinib for RET-mutant medullary thyroid cancer and RET fusion-positive th

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 04, 2020

  8/4/2020

  Blueprint Medicines Corporation announced that, effective on August 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,514 shares of its common stock and an aggregate of 7,255 restricted stock units to six new employees under Blueprint Medicines' 2020 Inducement Plan.

• Blueprint Medicines Reports Second Quarter 2020 Financial Results

  7/30/2020

  Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported financial results and provided a business update for the second quarter ended June 30, 2020.

• Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

  7/24/2020

   Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency's Committee for Medicin